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ABSTRACT
Background: Controlled hypotension is a technique that is used to limit 
intraoperative blood loss to provide the best possible surgical field during surgery.
Objective: The aim of this double-blind, randomized, controlled study was to 
compare the effects of desflurane combined with esmolol or dexmedetomidine on the 
amount of blood in the surgical field, recovery time, and tolerability in adult patients 
undergoing tympanoplasty.
Methods: Turkish patients aged 18 to 60 years, classified as American Society of 
Anesthesiologists physical status I or II, who were scheduled for tympanoplasty were 
randomly divided into 2 groups: the esmolol group or the dexmedetomidine group. After 
the anesthesia induction in the esmolol group, a loading dose of esmolol was infused in-
travenously over 1 minute at 1 mg/kg, followed by a maintenance rate of 0.4 to 0.8 mg/
kg/h. In the dexmedetomidine group, a loading dose of dexmedetomidine was infused 
intravenously over 10 minutes at a rate of 1 μg/kg, followed by a maintenance rate of 
0.4 to 0.8 μg/kg/h. The infusion rates were then titrated to maintain mean arterial 
pressure (MAP) of 65 to 75 mm Hg. General anesthesia was maintained with desflu-
rane 4% to 6%. Heart rate (HR) and MAP were recorded during anesthesia. The 
following 6-point scale was used to assess the amount of bleeding in the operative 
field: 0 = no bleeding, a virtually bloodless field; 1 = bleeding that was so mild that 
it was not a surgical nuisance; 2 = moderate bleeding that was a nuisance but did not 
interfere with accurate dissection; 3 = moderate bleeding that moderately compro-
mised surgical dissection; 4 = bleeding that was heavy but controllable and that sig-
nificantly interfered with surgical dissection; and 5 = massive bleeding that was un-
controllable and made dissection impossible. Scores ≤2 were considered to be optimal 
surgical conditions. The sedation score was determined at 15, 30, and 60 minutes 
after tracheal extubation using the following scale: 1 = anxious, agitated, or restless; 
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2 = cooperative, oriented, and tranquil; 3 = responsive to commands; 4 = asleep, but 
with brisk response to light, glabellar tap, or loud auditory stimulus; 5 = asleep, slug-
gish response to glabellar tap or auditory stimulus; and 6 = asleep, no response. Time to 
extubation and to total recovery from anesthesia (Aldrete score ≥9 on a scale of 0–10), 
adverse effects (eg, intraoperative hypotension [blood pressure <65 mm Hg], bradycar-
dia [HR <50 beats/min]), intraoperative fentanyl consumption, and postoperative nau-
sea and vomiting were recorded. Arterial blood gas analysis and kidney and liver func-
tion tests were conducted. All patients were evaluated by the same attending surgeon 
and anesthesiologist, both of whom were blinded to the administered study drugs.
Results: Fifty-two consecutive white patients undergoing tympanoplasty were 
identified. Two patients had to be excluded because of hypertension and 2 refused to 
participate. Forty-eight patients were equally randomized to either the esmolol group 
(n = 24 [16 women, 8 men]; mean [SD] age, 38.4 [10.5] years) or the dexmedetomi-
dine group (n = 24 [17 women, 7 men]; mean age, 35.5 [14.7] years). Sedation scores 
were not collected for 1 patient in the esmolol group; therefore, analysis was con-
ducted for 23 patients. The median (range) of the scores for the amount of blood in 
the surgical field in the esmolol and dexmedetomidine groups was 1 (0–3) and 1 (0–2), 
respectively (P = NS). Mean intraoperative fentanyl consumption in the esmolol group was 
significantly higher than in the dexmedetomidine group (50.0 [3.0] vs 25.0 [2.5] μg/min; 
P = 0.002). In the esmolol group, the mean times to extubation and to recovery from 
anesthesia were significantly shorter than those of the dexmedetomidine group (7.0 [1.4] 
vs 9.1 [1.9] minutes, respectively; 5.9 [2.1] vs 7.9 [2.3] minutes; both, P = 0.001). The 
mean sedation scores were significantly lower in the esmolol group (n = 23, because of 
intent-to-treat analysis) compared with the dexmedetomidine group at 15 minutes 
(2.5 [0.6] vs 3.6 [0.5]; P = 0.001) and 30 minutes (2.6 [0.6] vs 3.3 [0.6]; P = 0.001) 
postoperatively. No significant differences were found between the study groups in 
regard to blood urea nitrogen or creatinine concentration, aspartate aminotransferase 
or alanine aminotransferase activities, pH, partial pressure of carbon dioxide, or bicar-
bonate, before or after the operation.
Conclusions: Both esmolol and dexmedetomidine, combined with desflurane, 
provided an effective and well-tolerated method of achieving controlled hypotension 
to limit the amount of blood in the surgical field in these adult patients undergoing 
tympanoplasty. Esmolol was associated with significantly shorter extubation and re-
covery times and significantly less postoperative sedation compared with dexmedeto-
midine. (Curr Ther Res Clin Exp. 2009;70:197–208) © 2009 Excerpta Medica Inc.
Key words: esmolol, dexmedetomidine, desflurane, tympanoplasty, controlled 
hypotension.
INTRODUCTION
Controlled hypotension is a technique that is used to limit intraoperative blood loss 
to provide the best possible field for surgery.1,2 This technique has been used success-
fully for tympanoplasty.3 Various agents (eg, magnesium sulfate,4 sodium nitroprussi-
de,2 nicardipine,5 nitroglycerine,5 esmolol,2 α2-agonists,6–8 labetolol,9 and high doses 
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of potent inhaled anesthetics [eg, isoflurane10]) have been used to achieve controlled 
hypotension. Some of the disadvantages associated with these drugs include resistance 
to vasodilators, tachyphylaxis and cyanide toxicity with sodium nitroprusside, the pos-
sibility of myocardial depression with esmolol and magnesium sulfate, and a long 
postanesthetic recovery period with isoflurane. Apart from the adverse effects (AEs) of 
hypotension on vital organ perfusion, potent hypotensive agents also have their own 
concentration-dependent AEs that can be reduced by adjuvant treatment.11 When used 
alone, inhalational anesthetics require such a high concentration to achieve a significant 
reduction in bleeding that hepatic or renal injury might occur. Ideally, hypotensive 
agents should be easy to administer, have a short time to onset, have effects that disap-
pear quickly when administration is discontinued, have rapid elimination without 
toxic metabolites, have negligible effects on vital organs, and have predictable and 
dose-dependent effects.11
Hemostasis for the middle ear presents special problems for the anesthetist because 
even minimal bleeding impairs the surgeon’s vision and lengthens the time of sur-
gery.2,5 Esmolol is a short-acting β1-adrenoceptor antagonist12 and dexmedetomidine 
is a selective α2-adrenoceptor agonist.13 The efficacy of dexmedetomidine and esmolol 
for achieving controlled hypotension has been reported. Boezaart et al3 found that 
esmolol provided optimal surgical conditions compared with sodium nitroprusside for 
endoscopic sinus surgery during general anesthesia. The hypotension caused by a car-
dioselective β-adrenergic antagonist (esmolol) resulted in increased sympathetic tone 
of the mucous membrane arterioles that exerted unopposed α-adrenergic effects on the 
mucous membrane vasculature, causing capillary vasoconstriction. Durmus et al8 re-
ported that dexmedetomidine was associated with significantly decreased bleeding 
and intraoperative anesthetic requirements (both, P < 0.05) compared with placebo 
in patients undergoing tympanoplasty or septorhinoplasty. Richa et al7 compared the 
efficacy of dexmedetomidine with that of remifentanil for achieving controlled hy-
potension and improving surgical field exposure during tympanoplasty. They found 
that both remifentanil and dexmedetomidine administered intraoperatively were ef-
fective in decreasing arterial pressure and heart rate (HR) during tympanoplasty. In 
an experimental study, Lawrence et al14 found that dexmedetomidine was associated 
with a significant reduction in bleeding, especially in the skin, compared with base-
line (P < 0.05). Intraoperative-reduced bleeding may be due to the peripheral vaso-
constrictive effects of α2-agonists. 
Although esmolol is the most frequently used hypotensive agent for tympanoplas- 
ty,2,3 there have been few studies reporting the use of dexmedetomidine7,8 for this 
procedure. A review of the literature in MEDLINE was conducted of English- 
language texts (no year restrictions) using the following terms alone or in combination: 
controlled hypotension, tympanoplasty, esmolol, dexmedetomidine, and desflurane. The effica-
cies of desflurane combined with the β1-antagonist esmolol or with the α2-agonist 
dexmedetomidine have not been compared previously in tympanoplasty.
We designed this study to compare the effects of desflurane combined with esmolol 
or dexmedetomidine on the amount of blood in the surgical field, recovery time, and 
tolerability in adult patients undergoing tympanoplasty.
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PATIENTS AND METHODS
The study protocol was approved by the Human Ethics Committee of Cumhuriyet 
University School of Medicine (Sivas, Turkey), and written informed consent was ob-
tained from all study participants prior to study initiation.
Between February 2007 and March 2008, patients aged 18 to 60 years, classified 
as American Society of Anesthesiologists physical status I or II,15 who were scheduled 
for tympanoplasty were enrolled in this double-blind, randomized, controlled clinical 
study. Patients were excluded from the trial if they had significant dysrhythmia, in-
adequately controlled hypertension, preexisting coagulation defects, or had been re-
ceiving anticoagulant drugs or cardiovascularly active drugs as antiarrhythmic and 
antihypertensive agents. All patients were hospitalized at the Department of Otorhi-
nolaryngology Head and Neck Surgery, Cumhuriyet University School of Medicine, 
on the day before surgery and had fasted for ≥8 hours before surgery. All patients re-
ceived midazolam 0.07 mg/kg IM for sedation 30 minutes before surgery.
Randomization was achieved using sequentially numbered, opaque, sealed enve-
lopes containing computer-generated random allocations in a ratio of 1:1 in balanced 
blocks of 8.
On arrival in the operating room, 2 cannulae were inserted at different sites on the 
same arm, one for the infusion of esmolol or dexmedetomidine and the other for ad-
ministration of fluids and other drugs. A 22-G catheter was inserted into a radial ar-
tery for direct determination of arterial pressure and HR, which were recorded con-
tinuously. Before induction of anesthesia, baseline measurements of HR, mean arterial 
pressure (MAP), and oxygen saturation by pulse oximetry (SpO2) were obtained 
(Criticare System Inc., Waukesha, Wisconsin). A crystalloid solution (5 mL/kg) was 
administered at the start of the induction period and 100% oxygen was administered 
by mask for the first 3 minutes. Anesthesia was induced with fentanyl 1 μg/kg and 
propofol 2 mg/kg, and endotracheal intubation was facilitated with IV rocuronium 
0.6 mg/kg. Mechanical ventilation was adjusted to provide an end-tidal carbon diox-
ide (CO2) level of 30 to 35 mm Hg and an SpO2 level >95% with 50% air in oxygen. 
Infusions were initiated to achieve MAP between 65 and 75 mm Hg after tracheal 
intubation with esmolol or dexmedetomidine. In the esmolol group, a loading dose 
of esmolol was infused intravenously over 1 minute at 1 mg/kg, followed by a main-
tenance infusion rate of 0.4 to 0.8 mg/kg/h. In the dexmedetomidine group, a loading 
dose of dexmedetomidine was infused intravenously over 10 minutes at 1 μg/kg, fol-
lowed by a maintenance infusion rate of 0.4 to 0.8 μg/kg/h. The infusion rates were 
then titrated to maintain MAP between 65 and 75 mm Hg. General anesthesia was 
maintained with desflurane (end-tidal concentrations of desflurane, 4%–6%).
In both groups, signs of inadequate anesthesia (eg, increases in arterial pressure 
greater than the targeted MAP) or somatic responses (eg, movement, tearing, or 
sweating) were treated with additional fentanyl. Nitroglycerine was infused if these 
target limits could not be achieved with the uppermost dose. The drug infusion rate 
was then decreased when the targeted MAP was achieved. All study medications were 
administered by an anesthetist (I.O.K.) who was not involved in patient care or data 
collection. A second anesthetist (K.K.), who was blinded to treatment group, man-
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aged the patients. At the end of surgery, the amount of blood in the surgical field was 
rated by the same attending surgeon (A.Y.) who was blinded to the treatment groups 
and who performed all of the surgeries. The following 6-point scale16 was used to as-
sess the amount of bleeding in the surgical field: 0 = no bleeding, a virtually bloodless 
field; 1 = bleeding that was so mild that it was not a surgical nuisance; 2 = moderate 
bleeding that was a nuisance but did not interfere with accurate dissection; 3 = mod-
erate bleeding that moderately compromised surgical dissection; 4 = bleeding that 
was heavy but controllable and that significantly interfered with surgical dissection; 
and 5 = massive bleeding that was uncontrollable and made dissection impossible. 
Scores ≤2 were considered to be optimal surgical conditions. A local vasoconstrictor 
was not used to control bleeding at any time during the surgery.
Infusion of the study drugs was stopped 5 minutes before the anticipated end of 
surgery, and desflurane was stopped after skin closure. At the end of surgery, any re-
sidual neuromuscular blockade was antagonized with neostigmine and atropine. Ex-
tubation time and time to total recovery from anesthesia were recorded (Aldrete score 
≥9 on a scale of 0–10. Each variable was scored on a 3-point scale—consciousness 
[2 = fully awake; 1 = able to be roused on calling; 0 = not responding], activity [able 
to move voluntarily or on command: 2 = 4 extremities; 1 = 2 extremities; 0 = 0 ex-
tremities], respiration [2 = able to breathe deeply and cough freely; 1 = dyspnea, shal- 
low or limited breathing; 0 = apneic], circulation [2 = blood pressure (BP) ±<20 mm 
of preanesthetic level; 1 = BP ±20–50 mm of preanesthetic level; 0 = BP ±>50 mm 
of preanesthetic level], and SpO2 [2 = >92% on room air; 1 = needs oxygen inhala- 
tion to maintain SpO2 >90%; 0 = SpO2 <90% even with oxygen supple- 
mentation]–with a maximum achievable score of 10).17 After total recovery from 
anesthesia, patients were transferred to the recovery room. AEs (eg, intraoperative 
hypotension [BP <65 mm Hg], bradycardia [HR <50 beats/min]), intraoperative 
fentanyl consumption, and postoperative nausea and vomiting were recorded. Re-
quirements for an additional hypotensive agent (nitroglycerine) were also recorded. 
Arterial blood gas analysis was used to determine changes in pH, partial pressure of 
CO2 (PaCO2), and bicarbonate (HCO3). Blood samples were drawn immediately be-
fore surgery in the operating room to determine the baseline value and at 1 hour 
postoperatively in the recovery room. Blood samples were also drawn for blood urea 
nitrogen (BUN) and creatinine concentrations, and for aspartate aminotransferase 
(AST) and alanine aminotransaminase (ALT). The sedation score18 was measured using 
the following scale at 15, 30, and 60 minutes after tracheal extubation: 1 = anxious, 
agitated, or restless; 2 = cooperative, oriented, and tranquil; 3 = responsive to com-
mands; 4 = asleep, but with brisk response to light, glabellar tap, or loud auditory 
stimulus; 5 = asleep, sluggish response to glabellar tap or auditory stimulus; and 6 = 
asleep, no response.
Statistical Analysis
The number of patients enrolled in this study was determined based on our pre-
liminary analysis and a desired power of 80% to detect a between-group difference of 
20% in the scale used to assess the amount of blood in the surgical field with a sig-
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nificance level of 5%. Forty-four patients (22 in each arm of the study) would be 
needed for the study. Assuming a dropout rate of 15%, a total of 52 patients would 
need to be enrolled.
Data are mean (SD), median, or percentage. Statistical analyses were performed using 
Statistica software version 7.0 (Statsoft Inc., Tulsa, Oklahoma). Age, weight, duration of 
anesthesia and surgery, extubation time, time to complete recovery from anesthesia, BUN 
and creatinine concentrations, AST and ALT activities, pH, PaCO2, and HCO3 were 
compared using t tests. Sedation score, the amount of blood in the surgical field, and 
intraoperative fentanyl consumption were compared using the Mann-Whitney U test. 
Sex, the presence of a hypotensive agent, hypotension, bradycardia, and nausea and vomit-
ing were compared in the 2 groups using the χ2 test or Fisher exact test. MAP and HR 
were compared using repeated-measures analysis of variance. All post hoc comparisons 
were performed using Tukey tests. P < 0.05 was considered statistically significant. 
RESULTS
Fifty-two consecutive white patients undergoing tympanoplasty were identified. Two 
patients had to be excluded because of hypertension and 2 refused to participate. 
Forty-eight patients were equally randomized to either the esmolol group (n = 24 
[16 women, 8 men]; mean [SD] age, 38.4 [10.5] years) or the dexmedetomidine 
group (n = 24; [17 women, 7 men]; mean [SD] age, 35.5 [14.7] years). Sedation scores 
were not collected in 1 patient in the esmolol group; therefore, analysis was conducted 
for 23 patients. The durations of anesthesia and of surgery were similar in the esmolol 
and dexmedetomidine groups (Table I).
Of these 48 patients, 1 in the esmolol group was excluded from data analysis be-
cause the sedation scores were not properly recorded. Intent-to-treat analyses were 
carried out on all outcomes based on the original randomization.
Scores for a bloodless surgical field were low in both groups; there was no signifi-
cant difference in the between-group scores. The median (range) of the scores was 
Table I.  Demographic and clinical characteristics in adults undergoing tympanoplasty 
(N = 48).
 Esmolol Group Dexmedetomidine Group 
Characteristic (n = 24) (n = 24) P
Age, mean (SD), y 38.4 (10.5) 35.5 (14.7) 0.112
Sex, no. (%)   0.680
  Female 16 (66.7) 17 (70.8)
  Male 8 (33.3) 7 (29.2)
Weight, mean (SD), kg 72.9 (14.8) 68.8 (14.1) 0.993
Duration of anesthesia,  
mean (SD), min 84.8 (21.5) 82.3 (20.9) 0.796
Duration of surgery,  
mean (SD), min 73.3 (21.5) 72.1 (21.0) 0.834
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1 (0–3) in the esmolol group and 1 (0–2) in the dexmedetomidine group. The scores were 
≤2 throughout the study, except that 1 patient in the esmolol group had a score of 3. 
Mean (SD) intraoperative fentanyl consumption in the esmolol group was signifi-
cantly higher than in the dexmedetomidine group (50.0 [3.0] vs 25.0 [2.5] μg/min; 
P = 0.002). The mean time to extubation was significantly shorter in the esmolol 
group than in the dexmedetomidine group (7.0 [1.4] vs 9.1 [1.9] min; P = 0.001), as 
was the time to total recovery from anesthesia (Aldrete score ≥9) (5.9 [2.1] vs 7.9 [2.3] 
min; P = 0.001). The mean postoperative sedation scores were significantly lower in 
the esmolol group (n = 23 because of intent-to-treat analysis) than in the dexmedeto-
midine group at 15 minutes (2.5 [0.6] vs 3.6 [0.5] min; P = 0.001) and 30 min- 
utes (2.6 [0.6] vs 3.3 [0.6] min; P = 0.001). There was no significant between-group 
difference in the postoperative sedation score at 60 minutes (Table II).
There were no significant between-group differences in MAP (Figure 1) or HR 
(Figure 2) at baseline, after induction, or during the hypotensive period. MAP at the 
end of surgery was significantly higher in the esmolol group than in the dexmedeto-
midine group (P = 0.002). MAP and HR during the hypotensive period were signifi-
cantly lower than at baseline, after induction, and at the end of surgery in both groups 
(all, P < 0.05). 
There were no significant differences between the study groups in regard to BUN and 
creatinine clearance concentrations, AST and ALT activities, pH, PaCO2, and HCO3 at 
Table II.  Fentanyl requirements, recovery characteristics, and sedation scores by study 
group in adult patients undergoing tympanoplasty (N = 48). Data are mean (SD).
  Dexmedetomidine 
 Esmolol Group  Group 
Variable (n = 24) (n = 24) P
Intraoperative fentanyl consumption, μg 50.0 (3.0) 25.0 (2.5) 0.002
Time to extubation, min 7.0 (1.4) 9.1 (1.9) 0.001
Time to Aldrete score ≥9, min* 5.9 (2.1) 7.9 (2.3) 0.001
Sedation score 15 minutes after surgery† 2.5 (0.6) 3.6 (0.5) 0.001
Sedation score 30 minutes after surgery† 2.6 (0.6) 3.3 (0.6) 0.001
Sedation score 60 minutes after surgery† 2.0 (0.2) 2.1 (0.4) 0.176
* Aldrete scale17: Aldrete score ≥9 on a scale of 0 to 10. Each variable was scored on a 3-point scale—
consciousness (2 = fully awake; 1 = able to be roused on calling; 0 = not responding), activity (able 
to move voluntarily or on command: 2 = 4 extremities; 1 = 2 extremities; 0 = 0 extremities), respira-
tion (2 = able to breathe deeply and cough freely; 1 = dyspnea, shallow or limited breathing; 0 = 
apneic), circulation (2 = blood pressure [BP] ±<20 mm of preanesthetic level; 1 = BP ±20–50 mm of 
preanesthetic level; 0 = BP ±>50 mm of preanesthetic level), and Oxygen (O2) saturation (SpO2) (2 = 
>92% on room air; 1 = needs O2 inhalation to maintain SpO2 >90%; 0 = SpO2 <90% even with 
O2 supplementation)—with a maximum achievable score of 10.
†  Sedation score18: 1 = anxious, agitated, or restless; 2 = cooperative, oriented, and tranquil; 3 = 
responsive to commands; 4 = asleep, but with brisk response to light, glabellar tap, or loud auditory 
stimulus; 5 = asleep, sluggish response to glabellar tap or auditory stimulus; 6 = asleep, no response. 
Sedation scores were not collected in 1 patient in the esmolol group and analyzed for 23 patients.
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Figure 1.  Mean arterial pressure (MAP) by study group in adult patients undergoing tym-
panoplasty. Data are mean (SD). *P < 0.05 versus all other time points. †P = 
0.002 versus the esmolol group.
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Figure 2.  Heart rate (HR) by study group in adult patients undergoing tympanoplasty. 
Data are mean (SD). *P < 0.05 versus all other time points.
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preoperative and postoperative measurements (Table III). During the study, there were 
no episodes of hypotension or bradycardia and there was no need to use nitroglycerine 
as an additional hypotensive agent. No major AEs were observed in the study groups.
DISCUSSION
The present study found that esmolol or dexmedetomidine, when used in combina-
tion with desflurane, provided a comparably optimal surgical field. Both drugs were 
effective in reaching MAP of 65 to 75 mm Hg and ensured good surgical conditions. 
This study is the first to compare the effects of esmolol or dexmedetomidine com- 
bined with desflurane in providing controlled hypotension and improving surgical 
field exposure during tympanoplasty. Both agents demonstrated similar hemodynamic 
Table III.  Kidney and liver function tests and arterial blood gas analysis by study group in 
adult patients undergoing tympanoplasty (N = 48). Data are mean (SD).
   Dexmedetomidine 
  Esmolol Group Group 
Variable Normal (n = 24) (n = 24) P
BUN, mg/dL 8.0–20.0   
  Preoperative  10.4 (3.4) 12.4 (4.1) 0.288
  Postoperative  11.0 (3.1) 12.6 (4.8) 0.358
Creatinine clearance,  
mg/dL 0.7–1.2
  Preoperative  0.8 (0.2) 0.8 (0.2) 0.221
  Postoperative  0.8 (0.2) 0.8 (0.3) 0.763
AST, IU/L 15.0–41.0
  Preoperative  21.5 (9.4) 19.5 (5.8) 0.654
  Postoperative  19.6 (4.6) 19.0 (5.4) 0.335
ALT, IU/L 17.0–63.0
  Preoperative  20.2 (9.1) 20.6 (12.6) 0.806
  Postoperative  19.7 (10.9) 19.5 (13.4) 0.983
pH 7.35–7.45
  Preoperative  7.4 (0.1) 7.4 (0.1) 0.747
  Postoperative  7.4 (0.1) 7.4 (0.1) 0.747
PaCO2, mm Hg 35.0–45.0
  Preoperative   34.5 (5.8) 33.8 (5.8) 0.135
  Postoperative  32.3 (5.7) 30.2 (5.7) 0.097
HCO3, mol/L 21.0–28.0
  Preoperative  22.1 (3.7) 21.6 (3.5) 0.674
  Postoperative  22.1 (3.7) 21.6 (3.5) 0.674
BUN = blood urea nitrogen; AST = aspartate aminotransferase; ALT = alanine aminotransferase; PaCO2 = 
arterial partial pressure of carbon dioxide; HCO3 = bicarbonate.
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effects during tympanoplasty. The fentanyl requirement was significantly less with 
dexmedetomidine than with esmolol; however, dexmedetomidine was associated with 
significantly longer times to extubation and to total recovery from anesthesia, and 
significantly increased postoperative sedation scores. The clinical significance of these 
differences remains to be determined.
Our choice of targeted MAP was 65 to 75 mm Hg, which is considered moderate 
controlled hypotension.19,20 Controlled hypotension is associated with morbidity and 
mortality; ischemic organ failure resulting in death was found to be 0.02% to 0.06% 
in surgery involving controlled hypotension.21 Accordingly, we avoided profound 
controlled hypotension (MAP = 50 mm Hg). Intraoperative blood pressure and bleed-
ing at the surgical site are not necessarily correlated.
Decreasing MAP below 70 mm Hg may increase intraoperative bleeding due to 
local vasodilatation.3,22 In the present study, all patients except 1 had scores that in-
dicated good surgical conditions (0–2) during tympanoplasty. Fukusaki et al23 inves-
tigated the effects of controlled hypotension with nitroglycerine on hepatic function 
(MAP ~60 mm Hg). They reported that controlled hypotension was associated with 
an increase in AST and lactate dehydrogenase activities, although these values re-
mained within the normal range. In our study, normal liver and kidney functions were 
found in both groups, probably because MAP was maintained at >65 mm Hg in all 
patients. Using a high dose of inhalational anesthetics to decrease blood pressure is 
likely to be associated with prolonged recovery from anesthesia, delayed patient dis-
charge, and metabolic AEs.24 This use may also be associated with increased bleeding 
because of the peripheral vasodilating effects of inhaled anesthetics.
In our study, fentanyl consumption was significantly lower in the dexmedetomi-
dine group compared with the esmolol group. Several studies have found that peri- 
operative use of dexmedetomidine was associated with a significant decrease in the 
consumption of inhalational agents (P < 0.05),25 fentanyl (P < 0.05),26 and analgesics 
(P < 0.05)27 in a dose-dependent manner.25 We found that patients in the dexmedeto-
midine group had significantly higher postoperative sedation scores than those in the 
esmolol group. Dexmedetomidine has sedative and analgesia-sparing effects via central 
actions in the locus coeruleus and in the dorsal horn of the spinal cord, respectively.28,29 
Similar to our study, Richa et al7 reported that extubation time was significantly 
slower in patients receiving dexmedetomidine compared with those receiving remi- 
fentanil for controlled hypotension (P < 0.001).
Limitations
For bloodless surgical field data, post hoc power analysis suggested a power of 39%. 
For sedation score data, post hoc power analysis suggested a power of 100%. The 
numbers of patients in the study groups did not provide the expected power value for 
bleeding in surgical field data. Consequently, a type II error might have occurred due 
to low statistical power. Nonetheless, despite the low sample size, the present study 
indicated that esmolol and dexmedetomidine might be associated with similar success 
rates of controlled hypotension during tympanoplasty. Larger prospective, controlled 
studies are necessary to draw definitive conclusions about the effects of these drugs.
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CONCLUSIONS
Both esmolol and dexmedetomidine, combined with desflurane, provided an effective 
and well-tolerated method for achieving a bloodless surgical field with controlled 
hypotension in these patients undergoing tympanoplasty. Esmolol was associated with 
significantly shorter extubation and recovery times and significantly less postopera-
tive sedation compared with dexmedetomidine. 
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